XML 30 R20.htm IDEA: XBRL DOCUMENT
v3.22.2.2

CONCENTRATIONS | 9 Months Ended
--- | ---
Sep. 30, 2022
CONCENTRATIONS |
CONCENTRATIONS | NOTE (14) CONCENTRATIONS For the three months ended September 30, 2022, the Company sourced approximately 39% of the supplies for its electrotherapy products from two significant vendors. For the same period in 2021, the Company sourced approximately 51% of the supplies for its electrotherapy products from three significant vendors. For the nine months ended September 30, 2022, the Company sourced approximately 33% of supplies for its electrotherapy products from two significant vendors. For the same period in 2021, the Company sourced approximately 36% of supplies for its electrotherapy products from two significant vendors. At September 30, 2022, the Company had receivables from one third-party payer that made up approximately 15% of the net accounts receivable balance. At December 31, 2021, the Company had receivables from one third-party payer which made up approximately 22% of the net accounts receivable balance.

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -URI https://asc.fasb.org/topic&trid=2134479 + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration